Advertisement
A live webcast of the conference call can be accessed through thecompany's website at: www.emisphere.com. The live conference call dial-innumber is: 1-800-895-0198 (United States and Canada) or 1-785-424-1053(International). In addition, an archive of the webcast can be accessedthrough the same link. An audio replay of the call will be available followingthe conference call by calling 1-800-688-7036 (United States and Canada) or1-402-220-1346 (International).
Advertisement
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that focuseson a unique and improved delivery of therapeutic molecules and pharmaceuticalcompounds using its eligen(R) technology. These molecules and compounds couldbe currently available or are in preclinical or clinical development. Suchmolecules or compounds usually cannot be delivered by the oral route ofadministration or the benefits of these compounds are limited due to poorbioavailability, slow on-set of action or variable absorption. The eligen(R)technology can be applied to the oral route of administration as well otherdelivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal ortransdermal. The Website is: www.emisphere.com.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by representativesof Emisphere relating to matters that are not historical facts (includingwithout limitation those regarding future performance or financial results,the timing or potential outcomes of research collaborations or clinicaltrials, any market that might develop for any of Emisphere's productcandidates and the sufficiency of Emisphere's cash and other capitalresources) are forward-looking statements that involve risks anduncertainties, including, but not limited to, the likelihood that actualperformance or results could materially differ, that future research willprove successful, the likelihood that any product in the research pipelinewill receive regulatory approval in the United States or abroad, the abilityof Emisphere and/or its partners to develop, manufacture and commercializeproducts using Emisphere's drug delivery technology, or Emisphere's ability tofund such efforts with or without partners. Emisphere undertakes no obligationto update any of these statements. Readers are cautioned not to place unduereliance on these forward-looking statements, which speak only as to the datehereof. Accordingly any forward-looking statements should be read inconjunction with the additional risks and uncertainties detailed inEmisphere's filings with the Securities and Exchange Commission, includingthose factors discussed under the caption "Risk Factors" in Emisphere's AnnualReport on Form 10-K for the fiscal year ended December 31, 2007, filed onMarch 17, 2008, and our Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2007, filed on May 7, 2007 (file no. 000-17758), for the quarterended June 30, 2007, filed on August 7, 2007 (file No. 000-17758), and for thequarter ended September 30, 2007, filed on November 6, 2007 (000-17758).
SOURCE Emisphere Technologies, Inc.
